AMPA Receptor Agonists: Synthesis, Protolytic Properties, and Pharmacology of 3-Isothiazolol Bioisosteres of Glutamic Acid
- 1 February 1997
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 40 (4) , 520-527
- https://doi.org/10.1021/jm9607212
Abstract
A number of 3-isothiazolol bioisosteres of glutamic acid (1) and analogs of the AMPA receptor agonist, (RS)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid (AMPA, 2a), including (RS)-2-amino-3-(3-hydroxy-5-methylisothiazol-4-yl)propionic acid (thio-AMPA, 2b), were synthesized. Comparative in vitro pharmacological studies on this series of 3-isothiazolol and the corresponding 3-isoxazolol amino acids were performed using a series of receptor binding assays (IC50 values) and the electrophysiological rat cortical slice model (EC50 values). Whereas 2a (IC50 = 0.04 ± 0.005 μM, EC50 = 3.5 ± 0.2 μM) is markedly more potent than the tert-butyl analog ATPA (3a) (IC50 = 2.1 ± 0.16 μM, EC50 = 34 ± 2.4 μM) in [3H]AMPA binding and electrophysiological studies, 2b (IC50 = 1.8 ± 0.13 μM, EC50 = 15.0 ± 2.4 μM) was approximately equipotent with thio-ATPA (3b) (IC50 = 0.63 ± 0.07 μM, EC50 = 14 ± 1.3 μM). (RS)-2-Amino-3-(3-hydroxyisoxazol-5-yl)propionic acid (HIBO, 4a) was approximately equipotent with its thio analog 4b, whereas 4-Br-HIBO (5a) (IC50 = 0.65 ± 0.12 μM, EC50 = 22 ± 0.6 μM) turned out to be much more potent than the corresponding 3-isothiazolol 5b (IC50 = 17 ± 2.2 μM, EC50 = 500 ± 23 μM). 2b (ED50 = 130 μmol/kg) was more potent than 2a (220 μmol/kg) as a convulsant after subcutaneous administration in mice. The protolytic properties of 2a,b − 4a,b were determined using 13C NMR spectroscopy. For each pair of compounds, the α-amino acid groups showed similar protolytic properties, whereas the 3-isoxazolol moieties typically showed pKa values 2 units lower than those of the 3-isothiazolols. Accordingly, calculations of ionic species distributions revealed pronounced differences between 3-isoxazolol and 3-isothiazolol amino acids. No simple correlation between activity as AMPA agonists in vitro and pKa values of these compounds was apparent. On the other hand, the relative potencies of AMPA (2a) and thio-AMPA (2b) in vitro and in vivo may reflect that these compounds predominantly penetrate the blood−brain barrier as net uncharged diprotonated ionic species.Keywords
This publication has 30 references indexed in Scilit:
- Design of excitatory amino acid receptor agonists, partial agonists and antagonists: ibotenic acid as a key lead structureEuropean Journal of Medicinal Chemistry, 1996
- FUNCTIONAL PARTIAL AGONISM AT IONOTROPIC EXCITATORY AMINO ACID RECEPTORSNeurochemistry International, 1996
- Modulation of AMPA receptor function in relation to glutamatergic abnormalities in Alzheimer's diseaseBiomedicine & Pharmacotherapy, 1994
- Molecular pharmacology of the AMPA agonist, (S)-2-amino-3-(3-hydroxy-5-phenyl-4-isoxazolyl)propionic acid [(S)-APPA] and the AMPA antagonist, (R)-APPANeurochemistry International, 1994
- Resolution, Absolute Stereochemistry, and Pharmacology of the S-(+)- and R-(-)-Isomers of the Apparent Partial AMPA Receptor Agonist (R,S)-2-Amino-3-(3-hydroxy-5-phenylisoxazol-4-yl)propionic Acid [(R,S)-APPA]Journal of Medicinal Chemistry, 1994
- The Metabotropic Glutamate ReceptorsPublished by Springer Nature ,1994
- Excitatory Amino Acid Receptors in SchizophreniaSchizophrenia Bulletin, 1993
- Treatment of Alzheimer's DiseaseThe British Journal of Psychiatry, 1990
- Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's diseaseTrends in Neurosciences, 1990
- Pharmacology of Amineptine: Synthesis and UpdatingClinical Neuropharmacology, 1989